Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
11/17/2020
1
Joshua Lichtblau Jennifer Krusa, RPh, CHC Daniel Meier, JD, CHC
Director, Medicaid Fraud Division Chief Compliance Officer Partner
New Jersey Office of State Comptroller PharmScript Benesch Law
Enforcement and Compliancefor Pharmacies
Health Care Compliance Association2020 Healthcare Enforcement Compliance Conference
Enforcement and Compliance for
PharmaciesPresented by Joshua Lichtblau
Director, Medicaid Fraud DivisionNew Jersey Office of the State Comptroller
2
1
2
11/17/2020
2
Goals for today
To help you better understand:
• NJ Medicaid Overview/Regulatory Framework• Medicaid Documentation Requirements• MFD’s Program Integrity Role • Pharmacy Investigations – MFD Process • Medicaid Pharmacy – FWA Obligations • Consequences for Non-Compliance
3
What is Medicaid?
Medicaid is a joint Federal and State program that helps pay medical costs if individuals have limited income and resources or meet other requirements.
Medicaid is a voluntary program for providers. Providers who participate must know, accept and abide by Medicaid rules and policies.
4
Compliance
Guidelines
Regulations
3
4
11/17/2020
3
New Jersey Medicaid Program – High Level
1.8 million beneficiaries $15+ billion annual spend 5 Managed Care Organizations (MCOs) cover 96% of
the beneficiaries Program administered by DMAHS, Division within
DHS OSC/MFD oversees program integrity, MCOs oversee
own spend through audits/investigations5
Administration and Oversight
6
Department of Law & Public Safety
Division of Criminal Justice
Office of the Insurance Fraud Prosecutor
Medicaid Fraud Control Unit (MFCU)
Department of Human Services
Division of Medical Assistance and Health
Services (DMAHS)
Managed Care Organizations
Special Investigations Unit
Office of the State Comptroller
Medicaid Fraud Division
5
6
11/17/2020
4
Medicaid Program Oversight• The state contracts with the following MCOs:
• Aetna Better Health of New Jersey• Amerigroup New Jersey, Inc.• Horizon NJ Health• UnitedHealthcare Community Plan• WellCare Health Plans of NJ, Inc.
• DMAHS oversees the day-to-day operations of Medicaid • MFD oversees program integrity, including MCO efforts to
combat fraud, waste and abuse (FWA)7
Medicaid Program – Pharmacy Expenditures Approximately 2250+ in-state pharmacies and 1025 out of
state pharmacies with active licenses in NJ (as of 9/2020) Pharmacy expenditures – approx. $1.7 billion (2019) Billing process – (a) Encounter claims: pharmacy submits
claim = PBM pays = MCO submits payment info to DXC; (b) Fee For Service (FFS): pharmacy submits claim = DXC pays on behalf of DMAHS
8
7
8
11/17/2020
5
Claim Submission/Documentation
• It is the provider’s responsibility to ensure that claims submitted for payment reflect the actual service/product that was provided.
• It is incumbent upon providers to maintain accurate records that support all Medicaid claims.
9
Provider Responsibilities
Are employees properly licensed?
Are any employees excluded by any state or the federal government?
Is there a registered pharmacist on duty during all working hours?
10
9
10
11/17/2020
6
Sources of Cases
Law enforcement and MCOs
Hotline
Data analytics – JSURS, MFD investigators, DMU referrals
11
MFD Expectations:
Provider/counsel will act in good faith
Good faith includes o Responding to information requests in a timely mannero Providing accurate information in response to requesto Providing comprehensive responses
12
11
12
11/17/2020
7
Our Visit
MFD may:• Come unannounced • Interview the RPIC/Owner and any other
personnel • Provide document preservation letter• Request wholesaler list, prescription records
and signature logs if warranted• Review timely reversal of claims for
prescriptions not picked up13
MFD Inventory Protocol
• MFD Investigator analyzes claims reimbursed for select medications
• MFD requests wholesale invoices directly from the wholesalers for all purchases and returns made during investigation period
• The wholesale invoices are used to establish a beginning inventory
• MFD reconciles the claims data to the wholesale invoices to determine if an inventory shortage occurred during the investigation period
14
13
14
11/17/2020
8
Hard Copy Wholesale Invoice
15
Inventory Reconciliation Detail Report –Completed Example
16
Clm ICN IdnClm
Source Code
Clm Drug Label Name
Clm Service
Date
Clm Svc
Units
Drug Form Desc
Clm Payment Amount
Wholesaler Name
Drug Label NameInvoice
Date
Inventory Analysis
Pack SizeQty
Inventory Purchased
Inventory Change
Inventory Balance
TOBRADEX EYE OINTMENT12/06/13 McKesson TOBRADEX EYE OINTMENT12/09/13 4 1 4 4 4
201334150013097 FFS TOBRADEX EYE OINTMENT12/07/13 4 GM (SOLIDS)$166.29 (4) 0
201007250018920 FFS TRUVADA 200 MG-300 MG TABLET03/13/10 30 EACH (TABLETS)$981.99 (30) (30)
TRUVADA 200 MG-300 MG TABLET03/14/10 McKesson TRUVADA 200 MG-300 MG TABLET03/17/10 30 1 30 30 30
TRUVADA 200 MG-300 MG TABLET03/27/10 McKesson TRUVADA 200 MG-300 MG TABLET03/30/10 30 1 30 30 60
201009650032949 FFS TRUVADA 200 MG-300 MG TABLET04/06/10 30 EACH (TABLETS)$1,049.49 (30) 30
201009950017168 FFS TRUVADA 200 MG-300 MG TABLET04/09/10 30 EACH (TABLETS)$1,049.49 (30) 0
TRUVADA 200 MG-300 MG TABLET04/11/10 McKesson TRUVADA 200 MG-300 MG TABLET04/14/10 30 1 30 30 30
TRUVADA 200 MG-300 MG TABLET04/30/10 McKesson TRUVADA 200 MG-300 MG TABLET05/03/10 30 1 30 30 60
201012350026434 FFS TRUVADA 200 MG-300 MG TABLET05/03/10 30 EACH (TABLETS)$1,049.49 (30) 30
TRUVADA 200 MG-300 MG TABLET05/04/10 McKesson TRUVADA 200 MG-300 MG TABLET05/07/10 30 1 30 30 60
201012650018895 FFS TRUVADA 200 MG-300 MG TABLET05/06/10 30 EACH (TABLETS)$1,049.49 (30) 30
201019512081858 FFS TRUVADA 200 MG-300 MG TABLET05/13/10 30 EACH (TABLETS)$1,049.49 (30) 0
201015350039161 FFS TRUVADA 200 MG-300 MG TABLET06/02/10 30 EACH (TABLETS)$1,049.49 (30) (30)
TRUVADA 200 MG-300 MG TABLET06/06/10 McKesson TRUVADA 200 MG-300 MG TABLET06/09/10 30 1 30 30 30
201019512081847 FFS TRUVADA 200 MG-300 MG TABLET06/09/10 30 EACH (TABLETS)$1,049.49 (30) 0
TRUVADA 200 MG-300 MG TABLET06/27/10 McKesson TRUVADA 200 MG-300 MG TABLET06/30/10 30 1 30 30 30
201018050018949 FFS TRUVADA 200 MG-300 MG TABLET06/29/10 30 EACH (TABLETS)$1,049.49 (30) 0
TRUVADA 200 MG-300 MG TABLET07/04/10 McKesson TRUVADA 200 MG-300 MG TABLET07/07/10 30 1 30 30 30
201018750316241 FFS TRUVADA 200 MG-300 MG TABLET07/06/10 30 EACH (TABLETS)$989.73 (30) 0
201019650365708 FFS TRUVADA 200 MG-300 MG TABLET07/15/10 30 EACH (TABLETS)$989.73 (30) (30)
201020750309893 FFS TRUVADA 200 MG-300 MG TABLET07/26/10 30 EACH (TABLETS)$989.73 (30) (30)
15
16
11/17/2020
9
Compliance
• Ensure that a claim is submitted for the actual NDC of the product dispensed
• Quantity and days supply must reflect the prescriber’s order
• Bill Medicaid as payer of last resort• Due diligence
• Keep all prescription files/signature logs organized and complete
• Reverse payment for prescriptions not picked up• DOCUMENT!
17
Investigation – Next Steps
MFD completes investigation and provides Notice of Intent (NOI) to recover
Provider has opportunity to submit information/rebuttal
MFD considers provider submission and issues Notice of Claim (NOC)/Certificate of Debt (COD)
At same time as NOC/COD – MFD initiates withhold of Medicaid payments
Provider can settle with MFD through Settlement Agreement
18
17
18
11/17/2020
10
Possible Outcomes
• Pay amount identified in NOI• Resolve through Settlement Agreement
• Recovery• Corrective Action Plan• Possible penalty
• Litigate in Office of Administrative Law• Refer for criminal investigation – MFCU• Refer to NJ Board of Pharmacy
19
Post Settlement Compliance• Address areas identified through investigation• Improve new employee screening/background checks, and
regular re-screening• Institute training; develop P & Ps• Implement improved inventory controls• Retain a monitor who is required to provide MFD with
reports on required issues• MFD may re-investigate at a later date depending on the
significance of the initial findings• Second findings more likely to result in penalties/possible
exclusion action
• Document, document, document!20
19
20
11/17/2020
11
Enforcement and Compliance for Pharmacies: How To Prepare Now
PRESENTATION PREPARED FOR:
Healthcare Enforcement Compliance Conference
November 16 -18, 2020
21
The picture can't be displayed. Presenter Views for Education Purposes Only
22
Any views or advice offered in thispresentation are those of its authorsand should not be construed as theposition of PharmScript.
This presentation is provided withthe understanding that thepresenter is not engaged in legal orother professional services.
21
22
11/17/2020
12
Benjamin Franklin famously advised fire-threatened Philadelphians in 1736 that
“An ounce of prevention is worth a pound of cure.” Clearly, preventing fires is better than
fighting them.
23
Best Practice Suggestions
KNOW
when an audit occurs
DESIGNATE
response team
INFORM
legal counsel
CONTACT
auditor
ORGANIZE
documents
REVIEW
documents prior to submission
IDENTIFY
process deficiencies
DEVELOP
corrective action plans
NOTIFY
stakeholders of
audit results
SUBMIT
audit response timely
AUDIT/MONITOR corrective action plans
24
23
24
11/17/2020
13
know
• Plan ahead during provider application process.
• Centralize your incoming methods/pathways for receiving audit communications.
• Train your pharmacy managers/Pharmacists-in-Charge to prioritize and escalate audit requests.
How will your organization know when an audit is scheduled or about to happen.
25
designate
• Assign knowledgeable subject matter expert to lead response effort.
• Allocate resources to assist in response effort.
• Audit lead must track/log all audit requests, results, outcomes, etc.
• Past performance dictates future outcomes.
Who in your organization will lead the audit response effort.
26
25
26
11/17/2020
14
inform• Inform legal counsel of audit request.
• Discuss audit response plan.
• Determine advice needed if audit request is unclear.
• Involve counsel in corrective action planning.
Involve and engage legal counsel.
27
contact
• Assess response due date for realistic timely completion.
• Acknowledge receipt of audit.
• Negotiate an extension if needed.
• Determine/discuss logistics for providing audit response documents to auditor.
• Demonstrate partnership/positive attitude.
• Provide company point-of-contact.
• Document all communications with auditor.Once an audit request is received, contact auditor to acknowledge receipt and request extension if needed.
28
27
28
11/17/2020
15
organize
• Compile documents and records in the same sequence/order of items requested in the audit.
• Use the same naming convention written in the audit request or by the auditor.
• Prepare and label documents in easily understood format when compared to the audit’s request.
• For on-site audits, schedule appropriate lead to participate and set aside a separate room/conference room.
Compile documents for audit submission in an easy-to-follow format.
29
review
• Review final packet of documents prepared for submission.
• Confirm packet is organized and easy-to-follow.
• Perform mock audit to predict auditor’s probable findings.
• Make copies (paper or electronic) of all documents to be submitted, including cover letter.
Conduct assessment of final documents prepared for submission.
30
29
30
11/17/2020
16
identify and
develop
• Own your deficiencies.
• Determine scope of deficiencies (isolated, pattern, widespread).
• Develop corrective action plans now and implement.
• Involve legal counsel to assist in well written corrective action plans.
Identify deficiencies and develop proactive corrective action plans.
31
notify• Determine stakeholders requiring awareness.
Most likely will be corrective action plan owners/sponsors.
• Provide metrics and scope of audit deficiencies.
• Communicate identified problems (deficiencies) and recommend solutions (corrective action plans).
Notify stakeholders of audit results.
32
31
32
11/17/2020
17
submit • Be on time, better yet, be early.
• If you need more time, contact the auditor in advance.
Timely submit audit response, preferably before deadline.
33
audit and monitor
• Effective compliance programs develop auditing and monitoring strategies.
• Engage internal audit team.
• Do not become an ongoing target for repeat audits.
Maintain ongoing auditing and monitoring of corrective action plans.
34
33
34
11/17/2020
18
THANK YOU
Jennifer Krusa, RPh, CHCChief Compliance Officer
35
www.beneschlaw.com
Daniel M. Meier, Esq.Benesch, Friedlander, Coplan & Aronoff LLP
Enforcement and Compliance for Pharmacies Part 3: Resolution – Counsel’s Role
Health Care Compliance Association2020 Healthcare Enforcement Compliance Conference
35
36
11/17/2020
19
Goals• Understanding the roles of the Compliance
Officer (“CO”) and Legal Counsel• Understand how to maximize the
relationship between the CO and Legal Counsel
• Know when to handle matters internally and when to seek outside help (counsel / consultant)
37
Roles – Compliance Officer• Compliance Officer - Duties
– Develop and implement the elements of an effective compliance program– Generate policies and programs related to compliance issues– Develop and implement education and training programs– Conduct internal audits and compliance reviews– Report on the progress of the compliance program– Investigate and develop CAPs– Coordinate with HR– Assess the effectiveness of the compliance program and revise as necessary
• Sources for Compliance Officer Responsibilities– OIG Compliance Program Guidance – Federal Sentencing Guidelines, §8B2.1(b)(2)(C)– Practical Guidance for Health Care Governing Boards on Compliance
Oversight, 2015
38
37
38
11/17/2020
20
Roles – Legal Counsel• Legal Responsibilities
– Interpret rules and law– Respond to regulatory inquiries– Advise organization
• Compliance Functions– Privileged communications
• Sources– “The legal function advises the organization on the legal and regulatory risks
of its business strategies, providing advice and counsel to management and the Board about relevant laws and regulations that govern, relate to, or impact the organization. The function also defends the organization in legal proceedings and initiates legal proceedings against other parties if such action is warranted.”
• Practical Guidance for Health Care Governing Boards on Compliance Oversight, 2015
39
• Factors to consider to determine relationship• Compliance Officer as General Counsel?• Collaboration, not Cohabitation
– Examples• Policies• Facts• Analysis
• Cost considerations– Acceptable risk levels – not all risks are equal– Legally sufficient versus best practices
40
Relationship Between Legal & Compliance
39
40
11/17/2020
21
• Secure Attorney-Client Privilege– Internal Investigation
• Upjohn Co. v. United States, 449 U.S. 383 (1981)• In re Kellogg Brown & Root, Inc., 756 F.3d 754 (D.C. Cir. 2014)
– Confidential information between company and counsel– Legal advice versus business advice
• Anaya v. CBS Broad., Inc., 251 F.R.D. 645 (D.N.M. 2007)• United States ex rel. Baklid-Kunz v. Halifax Hospital Medical Center, 2012 WL 5415108 (M.D.
Fla. Nov. 6, 2012)• TVT Records v. Island Def Jam Music Group, 214 F.R.D 143 (S.D.N.Y. 2003) • Bank Brussels Lambert v. Credit Lyonnais (Suisse) S.A., 220 F. Supp. 2d 283 (S.D.N.Y. 2002)
41
When to Bring in an Attorney?
– In-house legal versus external legal– Compliance matters to be covered by A-C privilege– Proper protections to ensure A-C privilege– U.S. ex rel. Gale v. Omnicare, Inc., No. 1:10–CV–00127 (N.D. Ohio Oct. 4,
2013) • Finding that business communications made in business meetings when an
attorney is present are not protected from disclosure• Holding that the A-C privilege did not apply to documents drafted by a compliance
officer just because general counsel and other attorneys may have also received these documents
42
When to Bring in an Attorney?
41
42
11/17/2020
22
– Prepared in Anticipation of Litigation• U.S. v. Adlman, 134 F.3d 1194 (2d Cir. 1998)
– Test: “in light of the nature of the document and the factual situation in the particular case, the document can fairly be said to have been prepared or obtained because of the prospect of litigation.”
– Conclusion: attorney would not have prepared this analysis without the looming threat of possible litigation in the event that the proposed transaction was consummated.
– If documents “would have been created in essentially similar form irrespective of litigation,” it cannot be said that they meet the “because of” standard.
43
When to Bring in an Attorney?
Hypotheticals: (1) Customer Complaint(2) Regulatory Inquiry• Who gets involved?• Roles
44
When to Bring in an Attorney?
43
44
11/17/2020
23
Hypothetical: Customer Complaint• Who gets involved?
– Compliance response team – In-house counsel– General counsel– Consultant
• Roles– Fact gathering– Legal analysis– Response to complaint– Reporting obligations– Trending
45
When to Bring in an Attorney?
Hypothetical: Regulatory Inquiry• Considerations:
– Was inquiry routine as part of business process or from enforcement agency?– Is the issue serious?– Involve novel interpretations of the law, rules or policies?
• Who gets involved?– Compliance
• Routine business inquiry– Legal
• Provide buffer for compliance• Maintain privilege• Evaluate risk• Report to firm management
46
When to Bring in an Attorney?
45
46
11/17/2020
24
Don’t pretend you don’t have a problem if you do…
47
If you become the target of an investigation…
• The Government will often initiate an investigation by issuing a document request.
• It could take the form of an audit, a subpoena, or a civil investigative demand.
• Know how you would (should) respond to any such request.
• They also might pay you (or one of your people) a personal visit…
48
Launching an Investigation
47
48
11/17/2020
25
So what do I do when they come to interview me?!?!?!!?It could take the form of an audit, a subpoena, or a civil investigative demand.
There really is no polite way to say this…
49
Launching an Investigation
• Have appropriate protocols in place…• Coordinate with legal counsel ASAP• Remember, the government will have spent months gathering evidence
about your billing practices before they come knocking• Make sure your key people know how to respond• Whatever ‘first story’ you give is your story – or there are consequences to
changing it
50
Launching an Investigation
49
50
11/17/2020
26
Don’t make the mistakes that create their own problems…Don’t lie to government investigators.
Don’t destroy or alter documents.
Don’t try to figure it out by yourself.
They know more than you think… don’t see what you can get away with.
51
Launching an Investigation
• Don’t make the Government’s job easy• Have policies, implement them, check for compliance and effectiveness;• Keep detailed, accurate patient records;• If it seems too good to be true...• Stay advised of trends (both good and bad).
52
Launching an Investigation
51
52
11/17/2020
27
• The easiest way to avoid accusations of healthcare fraud is to keep careful watch of relevant laws, monitor your billing practices, and take immediate corrective action when errors are discovered during routine audits
53
Launching an Investigation
Oh… and don’t commit fraud!
What are the options after issues are identified?• Payback to MAC• OIG Self-Disclosure Protocol• SRDP Self-Disclosure Protocol
54
Next Steps
53
54
11/17/2020
28
The path of least resistance
55
Payback to MAC
• OIG Provider Self Disclosure Protocol – Procedure for health care providers to voluntarily identify, disclose, and resolve
instances of potential fraud involving Federal health care programs– Avoid cost and disruption associated with a government investigation and litigation
• Self disclosure must:– Specify the laws that were potentially violated– Waive any statute of limitations defense – Ensure that corrective actions are in place and misconduct has ceased – Be made within the later of 60 days after any overpayment is identified or the date
the next applicable cost report is due
• Timeline for investigation completion – Disclosing party must complete investigation within 90 days of the date of its initial
disclosure submission
OIG Self-Disclosure Protocol
56
55
56
11/17/2020
29
• Self disclosure protocol provides detailed instructions for disclosures related to – Erroneous billing– Excluded individuals– Anti-kickback and Stark violations
• Sets a minimum settlement for non-Anti-Kickback Statute violations
• Coordination between agencies pursuing enforcement action (CMS, DOJ, OIG)
• Online submission tool available at the OIG website
OIG Self-Disclosure Protocol
57
• Cooperation among the OIG & DOJ • CMS only accepts violations or potential violations of self-referral law. • If additional violations or potential violations of other criminal, civil, and
administrative laws send to OIG. • Cannot submit disclosure concurrently under SRDP and OIG’s Self-
Disclosure Protocol. • Coordination with Law Enforcement. • Corporate Integrity Agreements. • http://www.cms.gov/Medicare/Fraud-and-
Abuse/PhysicianSelfReferral/Self_Referral_Disclosure_Protocol.html
Self-Referral Disclosure Protocol (SRDP)
58
57
58
11/17/2020
30
Factors considered in compromising overpayments • Nature and extent of the improper or illegal practice • Timeliness of the self-disclosure • Cooperation in providing additional information • Litigation risk to CMS • Ability to pay
Self-Referral Disclosure Protocol (SRDP)
59
Disclosure Protocols OIG Provider Self Disclosure Protocol (SDP). The SDPprovides guidance on how to investigate conduct,quantify damages, and report the conduct to the OIG toresolve the potential liability under the OIG’s civilmonetary penalty authorities. The SDP is not availablefor disclosure of an arrangement that involves onlyliability under the Stark Law, without accompanyingpotential liability under the AKS for the samearrangement.
Use of the SDP will suspend the 60-day time periodpursuant to which reporting and repayment of anoverpayment must be made to avoid FCA liability.
CMS Self-Referral Disclosure Protocol (SRDP). The SRDP isintended to facilitate the resolution of only matters that, in thedisclosing party’s reasonable assessment, are actually orpotential violations of the Stark Law.
Use of the SRDP will suspend the 60-day time periodpursuant to which reporting and repayment of anoverpayment must be made to avoid FCA liability.
OIG Self-Disclosure Protocol vs Self-Referral Disclosure Protocol
60
59
60
11/17/2020
31
Daniel Meier, JC, CHCPartner
Benesch, Friedlander Coplan & Aronoff LLP
411 Hackensack Avenue, 3rd FloorHackensack, NJ 07601-6323
and
39 Broadway, 25th FloorNew York, NY 10006
www.beneschlaw.com
Questions or Comments
61
62
Thank you!New Jersey Office of State Comptroller
Joshua LichtblauDirector, Medicaid Fraud Division
PharmScriptJennifer Krusa, RPh, CHC
Chief Compliance [email protected]
732-853-8423
Benesch, Friedlander Coplan & Aronoff LLPDaniel Meier, JD, CHC
201-488-1013
61
62